161 related articles for article (PubMed ID: 21167528)
1. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
Stone NN; Stone MM; Rosenstein BS; Unger P; Stock RG
J Urol; 2011 Feb; 185(2):495-500. PubMed ID: 21167528
[TBL] [Abstract][Full Text] [Related]
2. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.
Munro NP; Al-Qaisieh B; Bownes P; Smith J; Carey B; Bottomley D; Ash D; Henry AM
Radiother Oncol; 2010 Jul; 96(1):34-7. PubMed ID: 20362348
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.
Pinkawa M; Piroth MD; Holy R; Fischedick K; Schaar S; Borchers H; Heidenreich A; Eble MJ
Radiother Oncol; 2010 Jul; 96(1):25-9. PubMed ID: 20231039
[TBL] [Abstract][Full Text] [Related]
4. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
5. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer.
D'Amico AV
J Clin Oncol; 2010 Jun; 28(16):2651-2. PubMed ID: 20421530
[No Abstract] [Full Text] [Related]
6. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
[TBL] [Abstract][Full Text] [Related]
7. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
9. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
10. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
[TBL] [Abstract][Full Text] [Related]
12. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
13. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
14. Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer.
Sumitomo M; Asakuma J; Sato A; Ito K; Nagakura K; Asano T
Int J Urol; 2010 Nov; 17(11):924-30. PubMed ID: 20969640
[TBL] [Abstract][Full Text] [Related]
15. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
16. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
17. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
18. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD; Kuban D; Levy LB; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Radiother Oncol; 2010 Jul; 96(1):6-12. PubMed ID: 20400191
[TBL] [Abstract][Full Text] [Related]
19. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.
Spalding AC; Daignault S; Sandler HM; Shah RB; Pan CC; Ray ME
Urology; 2007 May; 69(5):936-40. PubMed ID: 17482938
[TBL] [Abstract][Full Text] [Related]
20. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]